Sarepta Therapeutics Inc. (SRPT) Rating Reiterated by Oppenheimer Holdings Inc.
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reaffirmed by investment analysts at Oppenheimer Holdings Inc. in a research report issued to clients and investors on Monday. They currently have a $76.00 target price on the stock. Oppenheimer Holdings Inc.’s target price suggests a potential upside of 55.29% from the stock’s current price.
SRPT has been the subject of a number of other research reports. JMP Securities raised shares of Sarepta Therapeutics to an “outperform” rating and boosted their price objective for the company from $10.00 to $60.00 in a research report on Monday, September 19th. Royal Bank Of Canada raised shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $83.00 price objective for the company in a research report on Monday, September 19th. Cowen and Company reaffirmed an “outperform” rating and set a $64.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, October 5th. Leerink Swann reaffirmed an “underperform” rating and set a $5.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, August 4th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $102.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, September 30th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus price target of $63.31.
Sarepta Therapeutics (NASDAQ:SRPT) traded down 6.39% during midday trading on Monday, hitting $48.94. 4,715,756 shares of the stock were exchanged. The stock’s market cap is $2.34 billion. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $63.73. The firm’s 50-day moving average is $45.66 and its 200 day moving average is $26.92.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/sarepta-therapeutics-inc-srpt-rating-reiterated-by-oppenheimer-holdings-inc.html
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter last year, the business posted ($0.87) EPS. Equities research analysts expect that Sarepta Therapeutics will post ($4.23) EPS for the current fiscal year.
In related news, SVP David T. Howton sold 9,304 shares of the company’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $465,200.00. Following the completion of the sale, the senior vice president now owns 11,168 shares in the company, valued at approximately $558,400. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the sale, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the stock. State Street Corp increased its stake in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares during the period. Franklin Resources Inc. bought a new position in Sarepta Therapeutics during the first quarter valued at $13,506,000. A.R.T. Advisors LLC bought a new position in Sarepta Therapeutics during the first quarter valued at $7,461,000. Eagle Asset Management Inc. bought a new position in Sarepta Therapeutics during the second quarter valued at $6,756,000. Finally, Emerald Mutual Fund Advisers Trust bought a new position in Sarepta Therapeutics during the second quarter valued at $4,712,000. Institutional investors and hedge funds own 65.06% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.